Daiichi Sankyo Co., Ltd.

Industry

  • Biotechnology
  • Pharmaceuticals
    • Vaccines
    • Generic Drugs

Other Names/Subsidiaries

  • Ambit Biosciences
  • American Regent
  • Asubio Pharmaceuticals
  • Daiichi Sankyo Espha
  • Daiichi Sankyo Europe
  • Daiichi Sankyo Healthcare
  • Daiichi Sankyo India Pharma
  • Daiichi Sankyo RD Novare
  • Daiichi Sankyo Vaccine
  • Daiichi Sankyo Vietnam Company
  • Im
  • Kitasato
  • Kitasato Daiichi Sankyo K.K.
  • Kitasato Daiichi Sankyo Vaccine
  • Luitpold Pharmaceuticals (American Regent
  • PharmaForce)
  • Plexxikon
  • Ranbaxy Laboratories
  • ROXRO Pharma
  • Sankyo Pharma
  • Shanghai Xinshengyuan Pharmaceutical Group
  • Suntory Pharmaceutical
  • U3 Pharma
  • Zenotech Laboratories
See more in Biomedtracker

Latest on Daiichi Sankyo Co., Ltd.

Scrip

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

AstraZeneca has made “a very strong start in 2025” and is in “an unprecedented catalyst rich period,” according to CEO Pascal Soriot but his media call to discuss the firm’s first-quarter results was,

Scrip

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi Sankyo’s Phase III DESTINY-Breast09 clinical trial testing the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) plus Roche’s Perjeta (pertuzumab) is the first tri

Scrip

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

Gilead Sciences is looking to expand the reach of Trodelvy (sacituzumab govitecan-hziy) into the frontline setting of triple-negative breast cancer (TNBC) based on positive topline results in combinat

Scrip

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s